

CLINAM


European Foundation for Clinical Nanomedicine

3rd European Conference for Clinical Nanomedicine

Foyer-Exhibition and University Village

Monday, May 10, 8.45 am – Wednesday, May 12, 2010, 4.15 pm
Messe Schweiz, Hall L'Entrée, Basel, Switzerland

Updated Final Programme (28.4.2010)



Meetings on Sunday, May 9, 2010 before the conference

General Assembly of the European Society for Nanomedicine, Business-meeting 3.00 pm

Meeting of the International Society for Nanomedicine, Business-meeting 5.00 pm

Welcome Dinner with the Speakers of the Conference 7.45 pm

European Foundation for Clinical Nanomedicine Alemannengasse 12, P.O. Box, 4016 Basel, Switzerland
Phone + 41 61 695 93 95 Fax +41 61 695 93 90 www.clinam@clinam.org

The International Nanomedical Gathering of Clinicians and Technologists

The European Conference for Clinical Nanomedicine is the annual scientific conference uniting clinicians and nanoscientists with the common vision to apply nanoscience methods, tools and materials to the benefit of the patient. It is a conference with European emphasis and international participation. - The Clinam-Conference combines a strong clinical focus with leading edge technology and science, it has proven to be a very fruitful platform for problem- and solution- oriented discussion between physicians, scientists and engineers.

Topics and Key Issues

This conference will show the limits and horizon of the promises of Nanomedical tools, techniques, and materials in the context of prevalent and unsolved medical problems. It addresses clinical questions, questions of sustainability, toxicity, ethics, societal and environmental impact. The conference starts with the clinicians, reporting the unsolved problems in medicine in the following fields: ▪ Cardiology ▪ Oncology ▪ Neurology / Neurosurgery ▪ Dermatology ▪ Orphan diseases ▪ Inflammatory Disease ▪ Infections Diseases ▪ Surgery / Orthopaedics and Implants and ▪ Diabetes. Based on these reports it shall be discussed what are the Nanoscience Technologies at hand for solving these problems. What actually exists, and in what stage of development are the novel approaches?

CLINAM-University Village with University Performance-Posters and Demonstrations

The healthcare sector is experiencing turbulent times: Open Innovation provides both opportunities and challenges for the academic sector. In a comparatively new area such as Nanomedicine, worldwide competition makes it essential that translation of Nanomedicine becomes much more efficient. Universities are being offered leadership roles – however this is a global opportunity and if we do not seize the opportunities others will! We must align academic research in the nanosciences to help patients; the small academic team model is unlikely to succeed and multi-disciplinary knowledgeable teams will be essential. The CLINAM Nanomedicine University Village 2010 from May 10-12 will present novel approaches, new research projects and initial outcomes of research and experimental results. The following Universities and Institutes participate:

- University London (UK) • ETH Zürich (CH) • University Basel (CH) • University Copenhagen (DK) • University Saarbrücken (D) • University Strasbourg (F) • University Budapest (H) • University Graz, (A) • University Vienna (A) • University Innsbruck (A) • University Alexandria (ET) • University Rome (I) • University Grenoble (F) • Fraunhofer Institute for Chemical Technology ICT (D) • University Udine (I) • European Center for Nanomedicine (I) • Nanomedicine Group of the s.c.r.l., Basovizza (I) • University Trieste (I) • University Tel Aviv (IL) • University Freiburg (D) • University Porto (P) • University Hospital Basel (CH) • Karolinska Institutet, Department.Neuroscience (S) • Industrial pioneers in nanomedical applications show within the University Village their tools since their best target group are clinicians, the interdisciplinary group of experts in biology, chemistry and physics and the decision makers from research institutes and the pharmaceutical industry and last but not least the members from Universities.

All members of the University Village participate at the conference within the debate session on **Wednesday, May 12 at 10.50 am**. *This First Clinam University Village will facilitate faster R & D and further* • interaction between searchers on a highly interdisciplinary level • cooperation between universities • discussion up to a pre-competitive level • finding the novel profile of the university in 2020! • investigation of nanomedicine for the benefit of patients.

For the University Village a separate booklet will be handed out to the title of **The Bridge towards Cooperation, Translation and University Leadership**. The University Village is installed in midst of the area where coffee breaks and lunches are served.

Updated Final Programme (28.4.2010)

Monday, May 10, 2010 (Registration from 07.45 am until 4.00 pm)

Plenum Session

08.45 1. Opening of the Conference

Opening Address on behalf of the Organisers

Beat Löffler, MA, CEO of the European CLINAM-Foundation for Clinical Nanomedicine, Basel (CH)

Opening Address of the European Union

Dr. Roland Schenkel, European Commission, Director General of the Joint Research Centre (JRC), Brussels (B)

Opening Address on behalf of the Canton of Basel-Stadt

Dr. Carlo Conti, Chancellor of the Governing Council of the Canton Basel-Stadt, Vice-President of the board of the Swiss Conference of the Cantonal Ministers of Public Health, Basel (CH)

Opening Address on behalf of Switzerland

Federal Councillor Didier Burkhalter, Federal Department of Home Affairs, Bern (CH)

09.45 2. Roadmap to Translate the Knowledge to Practice (Introduction and Keynote Lecture)

Chair **Beat Löffler, MA**, CEO of the Clinam-Foundation for Clinical Nanomedicine, Basel (CH)

Introduction

1 *The Roadmap of Clinical Nanomedicine towards the Patient*

Prof. Dr. med. Patrick Hunziker, President of the European Society for Nanomedicine, Intensive Care Clinic of the University of Basel, Basel (CH)

10.10 Opening Keynote Lecture

2 *The Complexity of HIV Interaction with its Hosts as Revealed at the Nanometric Level*

Prof. Dr. med. Luc Montagnier, President and CEO of Nanectis Biotechnology SA and President of the World Foundation Aids Research and Prevention, UNESCO, Nobel Laureate, Paris (F)

10.45 Questions

11.00 Break

11.30 3. Unsolved Problems Waiting for Nanomedical Solutions 1 (5 Statements)

Chair **Prof. Dr. med. Patrick Hunziker**, President of the European Society for Nanomedicine, Basel (CH)

1 *Unsolved Problems in Modern Management of Coronary Artery Disease*

Prof. Dr. med. Frans van de Werf Director of the Leuven Clinical Coordinating Centre and of the Department of Cardiovascular Medicine, Leuven (B)

- 2 ***Unsolved Problems in Diabetes***
Prof. Dr. Thomas R. Pieber, Head, Division of Endocrinology and Nuclear Medicine, Department of Internal Medicine, Medical University of Graz, Graz (A)
- 3 ***Unsolved Problems In Bacterial Infections***
Prof. Dr. med. Winfried V. Kern, Head, Division of Infectious Diseases, Department of Medicine, Albert-Ludwigs-University, Center for Infectious Diseases & Travel Medicine, and Center for Chronic Immunodeficiency, University Hospital Freiburg and Member of the Executive Committee of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Freiburg (D)
- 4 ***Unsolved Problems in Lung Disease***
Prof. Dr. med. Michael A. Tamm, Head of Respiratory Medicine and Laboratory of Pulmonary Cell Research, University Hospital Basel (CH)
- 5 ***Unsolved Problems in Dermatology***
PD Dr. med Thomas Kündig, Head of Research, Department of Dermatology, Zürich University and University Hospital, Zürich (CH)
- 12.30 ***Questions & Discussion***
- 13.00 ***Lunch***
- 14.30 ***4. Nanoscience Technologies for Solving Medical Problems 1 (7 Statements)***
Chair **Prof. Dr. Wolfgang P. Meier**, Head of the Department for Chemistry and Physical Chemistry, University of Basel, Basel (CH)
- 1 ***New (bio) Materials for Nanodevice Construction***
Prof. Dr. Patrick Couvreur, Director UMR CNRS 8612, Physico-chimie, Pharmacotechnie et Biopharmacie, University of Paris-Sud, Chatenay-Malabry (F)
- 2 ***Using Self-Assembled Nanomaterials to Inhibit the Formation of Metastatic Cancer Stem Cell Colonies in Vitro***
Prof. Dr. Rutledge Ellis-Behnke, Massachusetts Institute of Technology Cambridge (USA) and University of Hong Kong (HK/RC)
- 3 ***Superparamagnetic Nanoparticles: the Universal Tool for Diagnosis and Therapy!?***
Prof. Dr. Heinrich Hofmann, EPFL, Laboratoire de Technologie des Poudres, Lausanne (CH)
- 4 ***Supramolecular Structures as Nanocarriers in Gene and Drug Delivery - Challenge to Smart Molecular Therapy***
Prof. Dr. Kazunori Kataoka, Department of Materials Engineering Graduate School of Engineering and Division of Clinical Biotechnology Center for Disease Biology and Integrative Medicine Graduate School of Medicine, The University of Tokyo, Tokyo (J)
- 5 ***Drug Delivery Across Biological Barriers: Intestines, Skin and Lung.***
Prof. Dr. Claus-Michael Lehr, Professor for Biopharmaceutics and Pharmaceutical Technology Saarland University, Saarbrücken (D)

- 6 ***Biofunctional Nanoparticles for Targeted Medical Imaging***
Prof. Dr. Marcus Textor, ETH Zürich, BioInterfaceGroup, Laboratory for Surface Science and Technology, Department of Materials, Zürich, (CH)
- 7 ***Immunotoxicity and Immunogenicity of Nanodrugs – Two Sides of a Coin?***
Prof. Dr. med. Dr. Sc. Janos Szebeni, Head Department of Nanomedicine Bay Zoltán Institute of Nanotechnology, Budapest (H)
- 16.00 ***Questions & Discussion***
- 16.30 ***Break***
- 17.15 ***5. Late Breaking and Ongoing Clinical Trials in Nanomedicine 1 (5 Statements)***
 Chair **Prof. Dr. Thomas R. Pieber**, Head, Division of Endocrinology and Nuclear Medicine, Department of Internal Medicine, Medical University of Graz, Graz (A)
Prof. Dr. med. Patrick Hunziker, President of the European Society for Nanomedicine, University Hospital Basel, Basel (CH)
- 1 ***Progress toward Phase I Human Trials Using a PAMAM Dendrimer Based MRI Contrast Agent for Lymphatic Imaging***
Prof. Dr. Donald Tomalia, Director of the National Dendrimer & Nanotechnology Center, Central Michigan University, Mt. Pleasant (USA)
- 2 ***Dermal Delivery of Biologics: Development and Phase II Clinical Trial of a Topical Interferon Alpha Delivery System for HPV Infections Cervical Dysplasia and Ano-genital Warts***
Prof. Dr. Marianna Foldvari, Canada Research in Biotechnology and Nanomedicine, School of Pharmacy, University of Waterloo, Waterloo (CDN)
- 3 ***Design of Lipid-based Nanoparticle (LNP) Formulations of siRNA for Systemic Use***
Prof. Dr. Pieter Cullis, Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver (CDN)
- 4 ***Immunostimulatory Nano-particles for the Causal Treatment of Allergic Rhinitis: Results from a Phase IIb Study in 300 Patients Suffering from House Dust Allergy***
Dr. Wolfgang A. Renner, CEO, Cytos Biotechnology Ltd, Schlieren (CH)
- 5 ***Clinical Investigation of DermaVir Nanomedicine in HIV-Infected Patients***
Prof. Dr. Julianna Lisziewicz, CEO of Genetic Immunity, Budapest (H)
- 18.15 ***Questions & Discussion***
- 19.00 ***Special Presentation of the ETP Nanomedicine***
The European Technology Platform Nanomedicine – the Complement to CLINAM
Bertrand Loubaton, MBA, Chair ETP Nanomedicine, Director, Pharmaceutical & Academic Research Collaboration, Academic Programs, GE Healthcare Europe, Paris/Brussels (F/B)
- 19.10 ***End of Conference Day 1***

19.40 **Official CLINAM Evening Event on behalf of the European Foundation for Clinical Nanomedicine**
Walking to St. Elisabeth Church

20.00 *Arrival at Church*

20.15 ***Dinner with targeted delivery surprise: “steel particles and metal 64 foot carriers”***

Tuesday, May 11, 2010 (Registration from 07.45 am until 4.00 pm)

08.00 **6. Emphasis Session on Cancer - Nanomedical Approaches**

Two Parallel Sessions A and B

Session A Cancer Nanomedicine

08.00 **1. Nanoparticles Interacting with Cells (4 Statements)**

Chair **Prof. Dr. med. Radek Skoda**, Chair of the Department of Biomedicine, University Hospital Basel, Basel (CH)

1 ***Cellular Binding & Uptake of Nano-Objects***

Dr. med. Volker Mailänder, Leader of the Joint Research Group between the University Clinic of Medicine III, Mainz and the Max Planck Institute for Polymer Science, Mainz (D)

2 ***Enzymatic Degradation of Nanoobjects***

Prof. Dr. Valerian E. Kagan, PhD, DSc, Vice Chair of the Department for Environmental and Occupational Health (EOH), University of Pittsburgh (USA)

3 ***Intracellular Handling, Trafficking and Breakdown of Nanoobjects***

PD Dr. Maija Vihinen-Ranta, Academy Research Fellow, NanoScience Center, Department of Biological and Environmental Science, University of Jyväskylä, Jyväskylä (FIN)

4 ***Biologic Pathways as Target of Nanodrugs – Targeting Cancer-Stem Cells Without Harming Normal Stem Cells***

Prof. Dr. Jan Mollenhauer, University of Southern Denmark Head Molecular Oncology Director of Lundbeckfonden Center of Excellence in Nanomedicine NanoCAN, Odense (DK)

08.50 ***Questions & Discussion***

09.20 **2. Nanoparticles Interacting with the Organism (3 Statements)**

Chair **Prof. Dr. Gert Storm**, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)

1 ***Cancer Vascularisation and Lymphatics – the Fundamental Access Routes for Targeted Therapies***

Prof. Gerhard Christofori, PhD, Head of the Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel (CH)

- 2 ***Uptake and Elimination Pathways of Nanoparticles***
Dr. Khuloud Al-Jamal, Senior Research Fellow, Nanomedicine Lab, University of London (UK)
- 3 ***Targeted Nanomedicines: Importance of Size, Ligands and EPR***
Prof. Dr. Gert Storm, Institute for Pharmaceutical Sciences, Utrecht University, Utrecht (NL)
- 09.55 ***Questions & Discussion***
- 10.20 ***Break***
- 10.50 ***3. Nanoparticles Interacting with Disease (3 Statements)***
Chair Prof. Dr. med. Peter Meier-Abt, Vice-principal, Head of Research, University of Basel, Basel (CH)
- 1 ***Approved and Late Breaking Nanopharmaceuticals for Use in Humans - A Portfolio***
Prof. Dr. Raj Bawa, MS, Patent Agent, Bawa Biotechnology Consulting, Ashburn, Adjunct Associate Professor, Biology Department, Rensselaer Polytechnic Institute, Troy (USA)
- 2 ***Advanced Functionality (Photodynamic Therapy, Artificial Organelles)***
Prof. Dr. med. Patrick Hunziker, Dep. Chief of the Intensive Care Clinic of the University of Basel, President of the European Society for Nanomedicine, Basel (CH)
- 3 ***Overview on Molecular Ligand- and Target-systems in Cancer***
Prof. Dr. Dario Neri, Professor for Biomacromolecules, Department of Chemistry Applied Biosciences, ETH and Cofounder of Philochem Ltd., Zürich (CH)
- 11.30 ***Questions & Discussion***
- 12.00 ***End of Session***
- (Continuation: Session 8 in Plenary Hall at 12.10)**
- Session B Nanomedical Approaches for Cancer Diagnosis, Imaging and Nanotoxicology**
- 08.00 ***1. In Vitro Diagnosis: Nanotech Biomarker Detection (3 Statements)***
Chair Patrick Boisseau, Coordinator of Nano2Life, PM, CEA-Leti, Grenoble (F)
- 1 ***Cancer Biomarkers – the Prospect of Nano-arrays for Cancer Proteomics***
Prof. Dr. med. Simo Schwartz, Jr., PhD, Nanomedicine Coordinator Molecular Biology and Biochemistry Research Center for Nanomedicine (CIBBIM-Nanomedicine) Vall d'Hebron University Hospital Research Institute, Barcelona (SP)
- 2 ***Lab-on-chip for Nucleic Acid and Protein Cancer Biomarkers***
Prof. Dr. med. François Berger, Université Joseph Fourier, Director of Unit “Nanomédecine et Cerveau” of INSERM, Grenoble (F)
- 3 ***Detection of Circulating Cancer Cells***
Prof. Dr. Silke Krol, Istituto Neurologico Carlo Besta, Milano - Fondazione IRCCS, Milano (I)

- 08.30 **Questions & Discussion**
- 09.05 **2. Nanotech Imaging & Monitoring (5 Statements)**
Chair **Prof. Dr. Lajos P. Balogh**, Editor-in-Chief, Nanomedicine, Nanotechnology, Biology and Medicine (Elsevier) and Member of the Executive Board, American Society for Nanomedicine, Amherst (USA)
- 1 **Nanomaterial MR Imaging for Cancer and Other Disease – Clinical / Preclinical**
Prof. Dr. Klaas Nicolay, Dept. of Biomedical Engineering, Technical University, Eindhoven (NL)
- 2 **Lipid Nanoparticles for Clinical Fluorescence Imaging**
Patrick Boisseau, Coordinator of Nano2Life, PM, CEA-Leti, Grenoble (F)
- 3 **Advantage of Nuclear Imaging (PET, SPECT) Using Multimodal Nanoparticles**
Dr. Frédéric Ducongé, CEA - INSERM U 1023 Laboratoire d'Imagerie de l'expression des gènes, Orsay (F)
- 4 **Magnetic and Optical Nanosystems for the Sentinel Nodes Detection**
Dr. Geneviève Pourroy, Institut de Physique et Chimie des matériaux, CNRS-ECPM, Université de Strasbourg, Strasbourg (F)
- 5 **Dendrimer Nanocomposites in the Imaging and Therapy of Cancer**
Prof. Dr. Lajos P. Balogh, Editor-in-Chief, Nanomedicine: Nanotechnology, Biology and Medicine (Elsevier) and Member of the Executive Board of the American Society for Nanomedicine, Amherst (USA)
- 09 55 **Questions & Discussion**
- 10.20 **Break**
- 10.50 **3. Nanotoxicology (3 Statements)**
Chair **Prof. Dr. Paul Borm**, CEO/CSO of Magnamedics Diagnostics BV, Geleen (NL)
- 1 **Abolishing Systemic Toxicity by Nano-formulation of Drugs**
Prof. Dr. Paul Borm, Director of Centre of Expertise in Life Sciences, Hogeschool Zuyd, Heerlen and CEO/CSO of Magnamedics Diagnostics BV, Geleen (NL)
- 2 **Expected and Unexpected Side Effects of Nanodrugs**
Dr. Laurent Lévy, CEO of Nanobiotix, and Co-President of the French Technology Platform on Nanomedicine (FTPN), Paris (F)
- 3 **Toxicokinetic Profile of Hard and Soft Nanoparticles**
Prof. Dr. Kostas Kostarelos, School of Pharmacy, University of London, London (UK)
- 11.20 **Questions & Discussion**
- 12.00 **End of Session**

Plenum Session

- 12.10 **7. Unsolved Problems in Cancer Therapy (Keynote Lecture and 1 Statement)**
Chair **Prof. Dr. med. François Berger**, Université Joseph Fourier, Director of Unit “Nanomédecine et Cerveau” of INSERM, Grenoble (F)
- Keynote Lecture*
- 1 ***The Therapy of Solid Tumors***
Prof. Dr. med. Kathy Pritchard-Jones, President of the European Society for Pediatric Oncology, Institute of Cancer Research, Sutton (UK)
- 12.30 ***Unsolved Problems in the Therapy of Haematological Cancer***
2 **Prof. Dr. med. Jakob R. Passweg**, Head of the Department of Haematology, University Clinic Geneva, Geneva (CH)
- 12.40 ***Questions & Discussion***
- 13.00 ***Lunch***
- 14.15 **8. Cancer Drugs – Clinical Trials in Nanomedicine (3 Statements)**
Chair **Prof. Dr. med. Kathy Pritchard-Jones**, Institute of Cancer Research, Sutton (UK)
Prof. Dr. med. Patrick Hunziker, European Society for Nanomedicine, Basel (CH)
- 1 ***Clinical Application of Nano-liposomal drugs for Cancer: Proven Advantages and Open Questions***
Prof. Dr. med. Alberto Gabizon, Hebrew University, Jerusalem (IL)
- 2 ***Thermotherapy with Magnetic Nanoparticles: Survival Benefit for Glioblastoma Multiforme Patients***
Dr. rer. nat. Andreas Jordan, CSO, magForce Nanotechnologie AG, Berlin (D)
- 3 ***Tracer Induced Therapy in Cancer Treatment***
Dr. med. Manfred G. Krukemeyer, Department of Radio-Oncology, Paracelsus-Hospital Germany, Osnabrück (D)
- 15.00 ***Questions & Discussion***
- 15.30 ***Break***
- 16.00 **9. Expectations, Facts and Perspectives of Nanocarriers and Nanoparticles (3 Keynote Lectures)**
Chair **Prof. Dr. Peter Paul Speiser**, Professor em., ETH Zürich, Forch (CH)
Prof. Dr. Heinrich Hofmann, EPFL, Laboratoire de Technologie des Poudres, Lausanne (CH)
- Keynote Lecture*
- 1 ***Multifunctional Pharmaceutical Nanocarriers: What we can expect***
Prof. Dr. Vladimir P. Torchilin, Ph.D, D.Sc, Distinguished Professor, Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston (USA)

Keynote Lecture

2 ***Nanotechnology and Nanomedicines for Macrophages: Past, Present and Future***

Prof. Dr. SM Moein Moghimi, Professor of Nanomedicine, Director, Centre for Pharmaceutical Nanotechnology and Nanotoxicology, Department of Pharmaceutics and Analytical Chemistry and NanoScience Center, University of Copenhagen, Copenhagen (DK)

Keynote Lecture

3 ***Ultrasmall Nanoparticles in Intradermal and Mucosal Vaccination***

Prof. Dr. Jeffrey Hubbell, Laboratory for Regenerative Medicine and Pharmacobiology, Institute of Bioengineering, Swiss Federal Institute of Technology (EPFL), Lausanne (CH)

17.10 ***Questions & Discussion***

17.35 ***Short break to go to parallel sessions***

17.40 **10. Nanoscience Technologies for Solving Medical Problems 2 and 3**

Two Parallel Sessions A and B

17.40 **Session A Nanoscience Technologies for Solving Medical Problems 2 (6 Statements)**

Chair

Prof. Dr. Giacinto Scoles, ELETTRA Synchrotron, SISSA and CBM, Area Science Park, Basovizza, Trieste (I) and Biology Department, Temple University, Philadelphia (USA)

1 ***Visual Single Cell Proteomics with Microfluidics: Vision and Preliminary Results***

Dr. Thomas Braun, Senior Scientist, University of Basel (CH)

2 ***Chemotherapy with Magnetic Nanoparticles – an Innovative Method for Local Cancer Treatment***

Prof. Dr. med. Christoph Alexiou, Head Division for Experimental Oncology and Nanomedicine at the Dept of Oto-Rhino-Laryngology, Head and Neck Surgery, University Hospital Erlangen (D)

3 ***Nanoparticles against Alzheimer's Disease: PEG-PACA Nanoparticles are Able to Link the A β -Peptide and Influence its Aggregation Kinetic***

Prof. Dr. Karine Andrieux, UMR CNRS 8612, Faculty of Pharmacy, Châtenay-Malabry (F)

4 ***In vivo molecular Imaging of Cancer Targeting Integrin $\alpha_v\beta_3$ using ^{125}I -labeled Gold Nanoparticles Conjugated with Cyclic RGD Peptides***

Prof. Dr. med Keon Wook Kang, Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul (ROK)

5 ***Crosslinked Micelles with Transiently Linked Drugs – an Ideal Drug Carrier System?***

Dr. Cristianne JF Rijcken, Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS) Faculty of Sciences, University Utrecht, Utrecht (NL)

6 ***Improving the Brain Delivery of Gold Nanoparticles by Conjugation with an Amphipathic Peptide***

Prof. Dr. Marcelo J. Kogan, Department of Pharmacology and Toxicology University of Chile, Santiago de Chile (RCH)

18.40 *Questions & Discussion*

19.10 *End of Conference Day 2*

17.40 **Session B Nanoscience Technologies for Solving Medical Problems 3 (5 Statements)**

Chair **Prof. Dr. Eder Leila Romero**, Director of the Nanomedicine Research Program (NRP), Universidad Nacional de Quilmes, Buenos Aires (RA)

1 *Therapeutic Blood Purification Using Functionalized Core / Shell Nanomagnets*
Inge Herrmann MSc, Institute for Chemical and Bioengineering, ETH Zürich, Zürich (CH)

2 *The Nanostructure of Human Teeth: Biologically Inspired Dental Treatments*
Prof. Dr. Bert Müller, Director of the Biomaterials Science Center, Basel (CH)

3 *Nanotech for Stents: A New Perspective*
Dr. med. Varvara Karagkiozaki AHEPA University Hospital Thessaloniki, and Lab for Thin Films Nanosystems & Nanometrology, Physics Department, Aristotle University of Thessaloniki, Thessaloniki (GR)

4 *Nanoemulsion based Novel Drug Delivery System of Thymoquinone for the Treatment of Epilepsy*
Dr. Shadab Ahmad Pathan, Research Scholar Dept. of Pharmaceutics Faculty of Pharmacy, Jamia Hamdard, New Delhi (IND)

5 *Multi-Functionalisation of Carbon Nanotubes for Targeted Drug Delivery*
Dr. Cécilia Ménard-Moyon, CNRS Researcher, Institut de Biologie Moléculaire et Cellulaire, Laboratoire d'Immunologie et Chimie Thérapeutiques UPR 9021, Strasbourg (F)

18.30 *Questions & Discussion*

19.10 *End of Conference Day 2*

19.15 *Apéritif*

20.15 *Speakers Dinner & for Guests of the Foundation*

Wednesday, May 12, 2010 (Registration from 07.30 am until 1.00 pm)

Plenum Session

08.00 **11. Unsolved Problems Waiting for Nanomedical Solutions 2 (3 Sessions)**

Chair **Prof. Dr. med. Matthias Pfisterer**, University Hospital Basel, Basel (CH)

1 *Unsolved Problems in Malaria*
Prof. Dr. Marcel Tanner, Director of the Swiss Tropical & Public Health Institute, Basel (CH)

2 ***Unsolved Problems in Hereditary Cancer***
PD Dr. med. Karl Heinemann, PhD Genetics Department, Children Hospital Basel (CH)

3 ***Blood Brain Barrier / Neurology***
The Unsolved Problem of Targeted Therapy to the Brain – How to Measure Efficiency
Prof. Dr. Margareta Hammarlund-Udenaes, Ph.D., Professor of Pharmacokinetics and Pharmacodynamics, Division of Pharmacokinetics and Drug Therapy Department of Pharmaceutical Biosciences, Uppsala University, Uppsala (S)

08.30 ***Questions & Discussion***

09.10 ***Break***

Two Parallel Sessions A and B

12. Technologies for Solving Medical Problems 4 / Ethics / Regulations University Village Debate

Session A Nanoscience Technologies / Ethics

09.40 ***1. Nanoscience Technologies for Solving Medical Problems 4 (7 Statements)***
Chair Prof. Dr. med. Hans Myhre, Surgeon at the University Hospital, Oslo (N)
Prof. Dr. med. Stephan Marsch, Head of the Intensive care Clinic, University Hospital Basel

1 ***Simulation Solutions for the Challenges in Nanomedicine***
PD Dr. Wolfgang Wenzel, Karlsruhe Institute of Technology, Institute for Nanotechnology, Karlsruhe (D)

2 ***New Insights on Multifunctional Nano-platform Against Cutaneous Leishmaniasis***
Prof. Dr. Eder Leila Romero, Director of the Nanomedicine Research Program (NRP), Universidad Nacional de Quilmes, Buenos Aires (RA)

3 ***Triple presentation on SPIONS***
a) Nano-Immunology: SPIONS Modulate Dendritic Cell Function and T Cell Responses
Dr. med. Christoph von Garnier, Respiratory Physician, Bern University Hospital, Bern (CH)

4 ***b) Multifunctional Use of Paramagnetic Iron Oxide Nanoparticles in Drug and Cell Delivery***
Prof. Dr. Paul Borm Director of Centre of Expertise in Life Sciences, Hogeschool Zuyd, Heerlen and CEO/CSO of Magnamedics Diagnostics BV, Geleen (NL)

5 ***c) Nanoparticles in Medicine - Regulated Entry and Orchestrated Trafficking, Where is the Risk?***
Prof. Dr. med. Peter Gehr, Chair of the Institute of Anatomy, University Bern, Bern (CH)

6 ***A New Formulation of Clobetasol Propionate Loaded Liposomes for Topical Application***
Dr. Xiomara Pérez-Gutiérrez, Full Researcher, Center for Pharmaceuticals Research and Development, Havana, (C)

7 ***Artemether Loaded Nanostructured Lipid Carriers (Nanoferries) for Antimalarial Activity: Preparation, Physicochemical Characterisation and in Vivo Antimalarial Activity***
Aditya Nayak, Senior Research Fellow, Department of Biochemistry Post Graduate Center, Kuvempu University, Davangere, Karnataka (IND)

10.40 ***Questions & Discussion***

11.10 **2. Ethics (3 Statements)**

Chair **Prof. Dr. Martin Erdmann**, Patrick Henry College, Purcellville, Virginia (USA)

1 ***The Ethical Component of Regulating Nanomedicine***

Dr. Richard Moore, Head of Nanomedicine and Lifesciences at the Institute of Nanotechnology, Stirling (UK)

2 ***Promises.. Progress.. Predicament - What will Nanomedicine Really Bring to Human Society?***

Dr. Donald Bruce, Edinethics Ltd., Edinburgh, Scotland (UK)

3 ***Should Humans aspire to become Posthumans? - The Prospects and Challenges of transformative Healthcare***

Prof. Dr. Martin Erdmann, Patrick Henry College, Purcellville, Virginia (USA)

11.40 ***Questions & Discussion***

(Continuation: Session12 in Plenary Hall at 12.00)

Session B Regulations-Session / University Village Debate

09.50 **1. Regulations and Industry Related Matters (4 Statements)**

Chair **Prof. Dr. med. Dr. h.c. Fritz Bühler**, Director of the European Centre for Pharmaceutical Medicine (ECPM), Basel (CH)

1 ***Translation Research from Bench to Clinic and its Cross-Reference with Regulatory Hindrance***

Prof. Dr. Rogério Gaspar, Nanomedicine & DDS group, iMed.UL and Faculty of Pharmacy, University of Lisbon, Lisbon (P)

2 ***What does Healthcare Translatability Mean for Nanomedicine– and Whose View Counts?***

Prof. Dr. Mike Eaton, Head of Biological Chemistry, UCB, Slough (UK)

3 ***Drug Loaded Immunonanoparticles in the Combat of Cancer Stem Cells - Safety and Efficacy Considerations***

Prof. Dr. Jürgen Borlak, Pharmaco- and Toxicogenomics, Medical School Hannover, Director of Fraunhofer Institute of Toxicology and Experimental Medicine, (Fh-ITEM), Head of Department 'Molecular Medicine and Medical Biotechnology, Hannover (D)

4 ***Predicting Toxicity and Environmental Relevance of Nanoparticles – a Regulatory Approach***

Prof. Dr. Wendelin Stark, Institute for Chemical and Bioengineering, ETH Zürich (CH)

10.30 **Questions & Discussion**

10.50 **2. University Village Debate with all Members of The 1st CLINAM University Village**

Chair **Prof. Dr. med. Patrick Hunziker**, President, European Society for Nanomedicine, Basel (CH)
Beat Löffler, MA, CEO, Clinam-Foundation for Clinical Nanomedicine, Basel (CH)

“The Bridge towards Cooperation, Translation and University Leadership”

• University London (UK) • ETH Zürich (CH) • University Basel (CH) • University Copenhagen (DK)
• University Saarbrücken (D) • University Strasbourg (F) • University Budapest (H) • University Graz, (A) • University Vienna (A) • University Innsbruck (A) • University Alexandria (ET) • University Rome (I)
• University Grenoble (F) • Fraunhofer Institute for Chemical Technology ICT (D) • University Udine (I)
• European Center for Nanomedicine (I) • Nanomedicine Group of the s.c.r.l., Basovizza (I) • University Trieste (I) • University Tel Aviv (IL) • University Freiburg (D) • University Porto (P) • University Hospital Basel (CH) • Karolinska Institutet, Department Neuroscience (S)

Plenum Session

12.00 **13. Nanoscience Technologies for Solving Medical Problems 5 (1 Keynote Lecture, 3 Statements)**

Chair **Prof. Dr. Christian Schönenberger**, Director of the Swiss Nanoscience Institute, Basel (CH)

Keynote Lecture

1 **Novel Facts for Carbon Nanotubes in Brain Disease Including First Data**

Prof. Dr. Kostas Kostarelos, School of Pharmacy, University of London, London (UK)

2 **Mechanotransduction: Mechanisms of Mechano-Chemical Signal Conversion**

Prof. Dr. Viola Vogel, Department of Materials Laboratory for Biologically Oriented Materials, ETH Zürich, Zürich (CH)

3 **Emerging Micromechanical and Nanofluidic Technologies for Medical Diagnostics**

Prof. Dr. Giacinto Scoles, ELETTRA Synchrotron, SISSA and CBM, Area Science Park, Basovizza, Trieste (I) and Biology Department, Temple University, Philadelphia (USA)

4 **A Safe and Efficient Lipidic Nanoparticle Carrier of Gold Porphyrin for the Treatment of Neuroblastoma**

Prof. Dr. Kenneth Kak Yuen Wong, Department of Surgery, LKS Faculty of Medicine, University of Hong Kong and Queen Mary Hospital, Hong Kong (HK/RC)

12.50 **Questions & Discussion**

13.15 **Lunch**

The CLINAM 2010 Panel

14.30 ***Saving Lives versus Avoiding Risks – In Developed and in Developing Countries***

Chair **Prof. Dr. med. Patrick Hunziker**, President, European Society for Nanomedicine, Basel (CH)
Beat Löffler, MA, CEO, Clinam-Foundation for Clinical Nanomedicine, Basel (CH)

The fundamental motivation of medicine is to benefit the patient without adding harm. How can benefit be defined or measured for individuals, and what is risk in science for society? How can a benefit for an individual or a group of patients be weighted in relation to potential or unknown risks? Is it ethical to treat a human individual with a lethal disease with a novel therapeutic approach of uncertain efficacy or unproven safety or is it more ethical to withhold the therapy? Is the current practice of drug development suited to individual severe disease, to orphan disease, in children, in the elderly, in the developing countries? Facing the nanomedicine paradigm of composite therapeutic systems that can be tailored to an individual patient, what new avenues in drug development and regulation need to be taken?

Participants:

Prof. Dr. Werner Arber, Nobel Laureate Medicine 1978, Basel (CH)

Dr. Donald Bruce, Edinethics, Scotland (UK)

Prof. med. Matthias Pfisterer, University Hospital Basel, Basel (CH)

Dr. Heinrich Rohrer, Nobel Laureate Physics 1986, Wollerau (CH)

Dr. Beat Schmid, Head of Preclinical Review, Swissmedic, Bern (CH)

Dr. Andreas Wallnöfer, Global Head Clinical Research and Exploratory Development,
F. Hoffmann-La Roche, AG Basel (CH)

Prof. Dr. Jean Marie Lehn, ISIS, Université Louis Pasteur, Strasbourg and Collège de France, Paris,
Nobel Laureate Chemistry 1987, Strasbourg (F) (tbc)

Alastair Kent, Director of the Genetic Interest Group, Chair of the European Platform for Patients
Organisations, Science and Industry (EPPOSI), London (UK),

Mayeul Boucaumont, PharmD, Scientific Support & Projects, European Medicines Agency (EMA),
London (UK)

Dr. med. Birka Lehmann, Alternate Member of the Paediatric Committee (PDCO), Head of Licencing
Division 3, Federal Institute for Drugs and Medical Devices (BfArM) and Chair Nanomedicine Working
Group BfArM, Bonn (D)

16.00 ***Closing remarks***

Prof. Dr. med. Patrick Hunziker, President, European Society for Nanomedicine, Basel (CH)

16.15 ***End of conference***

Scientific Committee of the Conference

Chairpersons

- **Prof. Dr. med. Patrick Hunziker**, President of the European Society for Nanomedicine, Basel (CH)
(*Medical Chair*)
- **Prof. Dr. Gert Storm**, Member of the Board of Trustees of the CLINAM-Foundation, Utrecht (NL)
(*Scientific Chair*)

Members

- **Prof. Dr. Giacinto Scoles**, ELETTRA Synchrotron, SISSA and CBM, Area Science Park, Basovizza, Trieste (I)
- **Prof. Dr. Joachim Seelig**, Biozentrum, University, Basel (CH)
- **Beat Löffler, MA**, CEO of the Clinam-Foundation for Clinical Nanomedicine, Basel (CH)
- **Prof. Dr. med. Matthias Pfisterer**, University Hospital Basel (CH)
- **Prof. Dr. Marcus Textor**, Head of Laboratory for Surface Science and Technology, ETH Zürich (CH)
- **Patrick Boisseau**, Member of the Board of the European Technology Platform for Nanomedicine, Grenoble (F)
- **Dr. med. Dieter Scholer**, Member of the Swiss Academy of Medical Sciences, Basel (CH)
- **Prof. Dr. med Janos Szebeni**, Head Department of Nanomedicine Bay Zoltán Institute of Nanotechnology, Budapest (H)

General Information

Event Scheduling

Business Meetings on **Sunday**, May 9, 3 pm until 6 pm and Welcome Dinner for speakers 7.45 pm
(General Assemblies of the European and International Societies for Nanomedicine)

Conference as from **Monday** May 10, 8.45 am until **Wednesday** May 12, 4.15 pm

Exhibition as from **Monday**, May 10, 8.45. am until **Wednesday**, May 12, 2010, 2 pm

University Village as from **Monday**, May 10, 2010, 8.45 am until **Wednesday**, May 12, 4.15 pm

Organisers

The European CLINAM Foundation for Clinical Nanomedicine, Basel, Switzerland (www.clinam.org)
in cooperation with the European Society for Nanomedicine, Basel, Switzerland (www.esnam.org)

Responsible: Beat Löffler, MA, CEO and **Prof Dr. med. Patrick Hunziker**, CSO of the CLINAM-Foundation for Clinical Nanomedicine, Basel, Switzerland.

Office

European Foundation for Clinical Nanomedicine Alemannengasse 12, P.O. Box, CH-4016 Basel, Switzerland
Phone: + 41 61 695 93 95 Fax: + 41 61 695 93 90 Mail: clinam@clinam.org

Accommodation

The official conference hotel is the Swissôtel Le Plaza***** in 200 m distance from the conference hall. **All participants have a special room rate of CHF 285. – (about 175. – Euro), if indicating their participation in the Nanomedicine-Conference.** Booking: Swissôtel Le Plaza, CH-4005 Basel, phone +41 61 555 3333
E-Mail: <https://reservations.swissotel.com/Availability.aspx?property=SBA&promo=GCL&lang=en>

Other hotels can be provided through Basel Tourism: 4-star hotels CHF 180.00 - 220.00, 3-star hotels: CHF 150.00-180.00, 2-star hotels: CHF 130.00 - 150.00 Booking through: Basel Tourism Tel. +41 61 268 68 58 online on www.basel.com under “accommodation”.

Conference Fees

	Fee 3 days	Fee after April 23	One day	One day after April 23	
Academy esnam member	580. -- €	620. -- €	230. -- €	270. -- €	When receiving your registration the organiser shall send to you an invoice to be paid before start of the conference
Academy regular	725. -- €	765. -- €	320. -- €	360. -- €	
Industry esnam	895. -- €	935. -- €	520. -- €	560. -- €	
Industry regular	995. -- €	1'035.-- €	595. -- €	635. -- €	
Student esnam member	385. -- €	425. -- €	150. -- €	190. -- €	
Student regular	485. -- €	500. -- €	210. -- €	250. -- €	
Evening Event on May 10: Tickets are sold on basis “first come first served”					
Your contribution to the expenses is 50. -- € (please mark)					
Please note: A surcharge 25% will be added for registration on site					

Cancellations / Substitutions

The following charges will apply upon cancellation: Until February 10, 2010 20% and after that 50%. Refunding after March 25 is not possible. The dates refer to receipt of the cancellation notice. Substitutions can be made at any time.

Registration Desk

The registration Desk will be open at the following times:

Sunday	May 09, 2010	1.00 pm until 5.00 pm
Monday	May 10, 2010	7.45 am until 4.00 pm
Tuesday	May 11, 2010	7.45 am until 4.00 pm
Wednesday	May 12, 2010	7.45 am until 1.00 pm

Target Audience

The conference addresses clinical physicians as well as nanoscientists with a background of pharmacology, biology, physics, chemistry and engineering involved in the development and clinical application of nanomedicine. The conference is also of interest for policymakers, experts from industry in the field of life sciences and those involved in the development of new tools and materials for nanomedicine, as well as all those investigating the potential of future emerging technologies.

Changes of the Conference programme

This programme is subject to eventual changes

Liability for Exhibition and University Village

A general liability insurance has been signed for the duration of the conference by the organiser. However this does not include damages or theft of goods within the exhibition and the university village or the conference halls.

Aims and Structures of Organising Bodies

The European CLINAM-Foundation for Clinical Nanomedicine

is a non-profit institution aiming at advancing medicine to the benefit of individuals and society through the application of Nanoscience in medicine. Aiming at prevention, diagnosis, and therapy through Nanomedicine as well as at exploration of its implications, the Foundation reaches its goals through support of clinically focussed research and of interaction and information flow between clinicians, researchers, the public, and other stakeholders. The recognition of the large future impact of Nanoscience on medicine and the observed rapid advance of medical applications of Nanoscience has been the main reasons for the creation of the Foundation.

The European Society for Nanomedicine

was founded in April 2007 The Society is a registered, non-profit, non-governmental organisation with seat in Basel, Switzerland. It is the platform for all experts involved in clinical Nanomedicine. It is the forum for debating on a multidisciplinary clinical level and to establish professional contacts between clinicians, researchers at the universities and in the industry as well as developing alliances with the engineers and technicians who develop tools for clinical Nanomedicine. The Society is the bridge for all in clinical Nanomedicine involved experts to create together an interdisciplinary clinical forum and furthering the translation from research and development to products for the benefit of the patient. www.esnam.org

Board of Trustees of the European Foundation for Clinical Nanomedicine

- Dr. iur. Alexander Gutmans (President)
- Prof. Dr. med. Patrick Hunziker
- Beat Löffler, MA
- Prof. Dr. Hans Joachim Güntherodt
- Susy Hunziker, lic. phil.
- Prof. Dr. med. Matthias Pfisterer
- Prof. Dr. med. Stephan Marsch
- Prof. Dr. Gert Storm

European Society for Nanomedicine - Executive Council

- Prof. Dr. med. Patrick Hunziker (President)
- Beat Löffler, MA (Secretary General)
- Prof. Dr. med. Jacques-André Bazex
- Dr. Frank Sinner
- Prof. Dr. med. Hans Myhre
- Prof. Dr. Gert Storm
- Prof. Dr. med. Dr. h.c. Fritz Bühler
- Prof. Dr. Jacques Chambron
- Prof. Dr. Joachim Seelig

The Members of the Advisory Board of the CLINAM-Foundation

- **Prof. Dr. Dr. h.c. Zhores Alferov**, Physicist, Nobel Laureate, Moscow
- **Prof. Dr. Werner Arber**, Biologist and Biophysicist, Nobel Laureate, Basel
- **Prof. Dr. med. Jacques-André Bazex**, Member of the French National Academy of Medicine, Toulouse
- **Patrick Boisseau**, CEA-Leti-Minatec, Grenoble and Member of the Board of the European Technology Platform for Nanomedicine (ETPN), Brussels / Grenoble
- **Prof. Dr. Dr. h.c. Fritz Bühler**, Director of the European Centre for Pharmaceutical Medicine (ECPM), Basel
- **Dr. med. Victor Brantl, M.Sc.**, Vice-President, R&D, Mepha Ltd, Aesch,
- **Dr. Andreas Burckhardt**, Director of the Basel Chamber of Commerce, Basel
- **Dr. Peter Burckhardt**, CEO of EVA, The Basel Life Sciences Start-up Agency and BASEL INCUBAROR, Basel
- **Dr. Beat Butz**, Coordinator of the Swiss National Foundation, Bern
- **Prof. Dr. med. Jacques Chambron**, French Academy of Sciences, Strasbourg/Paris
- **Prof. Dr. med. Patrick Couvreur**, Director of the Centre d'études Pharmaceutiques (CNRS), Paris
- **Dr. Christoph Eymann**, Member of the Governing Council of the Canton of Basel, Basel
- **Prof. Dr. Theodor W. Guentert**, Senior Vice President Non-clinical Safety, F. Hoffmann-La Roche Ltd. Basel
- **Prof. Dr. Gerda Huber**, Director of School of Life Sciences, Muttentz, Switzerland
- **Prof. Dr. Kazunori Kataoka**, Head of Graduate School of Engineering and Division of Clinical Biotechnology, Graduate School of Medicine, The University of Tokyo
- **Prof. Dr. Silke Krol**, Istituto Neurologico Carlo Besta Milano - Fondazione IRCCS, Milano
- **Prof. Dr. Kostas Kostarelos**, Chairholder Nanomedicine, University of London
- **Prof. Dr. Karl J. Lackner**, President, German Association for Clinical Chemistry & Laboratory Medicine, Mainz
- **Prof. Dr. Jean Marie Lehn**, ISIS, Université Louis Pasteur, Strasbourg and Collège de France, Paris, Nobel Laureate
- **Prof. Dr. med. Klaus Lindpaintner, MPH, FACP**, Vice President, R&D, and Chief Scientific Officer, Strategic Diagnostics Inc., Newark,
- **Prof. Dr. Stergios Logothetidis**, Aristotele University of Thessaloniki,
- **Prof. Dr. med. Peter Meier-Abt**, Vice-principal and Head of Research, University of Basel
- **Prof. Dr. Hans Myhre**, Surgeon at the University Hospital, Oslo
- **Dr. Romeo Paioni**, Head of Scientific and External Affairs, Novartis, Basel
- **Dr. Heinrich Rohrer**, Physicist, Nobel Laureate, Wollerau
- **Dr. med. Dieter Scholer**, member of the Swiss Academy of Medical Sciences, Basel
- **Prof. Dr. med. Jürg Schifferli**, Head Internal Medicine, University Hospital and former board member of the Swiss National Foundation, Basel
- **Prof. Dr. Giacinto Scoles**, ELETTRA Synchrotron, SISSA & CBM, Area Science Park, Basovizza, Trieste (I)
- **Prof. Dr. Joachim Seelig**, Biozentrum, Basel
- **Prof. Dr. Christian Schönenberger**, Director of the Swiss Nanoscience Institute, Basel
- **Prof. Dr. Paul Siffert**, Secretary General, European Research & Materials Society, (EMRS) Strasbourg
- **Dr. Frank Sinner**, Director of the BioNanoNet-Research Society, Graz
- **Prof. Dr. med. Dr. Sc. Janos Szebeni**, Head of Department of Nanomedicine, Bay Zoltán Institute of Nanotechnology, Budapest
- **Prof. Dr. Donald Tomalia**, Director of the National Dendrimer & Nanotechnology Center, Central Michigan University, Mt. Pleasant
- **Dr. med. Panagiotis Trohopoulos**, Cardiologist and Nano-Physician, Thessalonica

**The reasons to attend the
3rd European Conference for Clinical Nanomedicine from
May 10 – 12 in Basel, Switzerland**

- Meet at the established interdisciplinary event on clinical nanomedicine in Europe.
- Attend the clinical meeting to further with your knowledge the acceleration of the development of Nanomedicine.
- Use the largest platform in Europe for clinical debate between researchers, scientists, engineers, clinicians and experts from medicine, physics, chemistry, pharmacy, biology, biochemistry and materials science.
- Discuss the promise and limits and implications of nanomedical tools, techniques and materials in the context of unsolved medical problems and investigate the clinical evidence of established nanodrugs.
- See some pioneer-companies in the field of nanomedicine.
- Participate in the translation of nanomedical research into products to the benefit of the patient.
- Talk to the representatives from the universities in the “University Village” and learn about their role to translate nanomedicine from research to products.

Welcome in Basel from May 10-12, 2010 (preceded on May 9 by the Business Meetings of the European Society for Nanomedicine (esnam) and International Society for Nanomedicine (ISNM))

CLINAM

European Conference for Clinical Nanomedicine, May 10-12, 2010
CONFERENCE REGISTRATION FORM

I register for the **Third European Conference for Clinical Nanomedicine.**

	Regular	Member	Early Registration
Academy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Industry	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Students	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Exhibitor ticket (**Transferable**) **780. -- €**; (only **one** transferable ticket per exhibitor)

I participate in the **evening event** on May 10, 2010 at the support rate of 50. -- €

Title: _____ Last name: _____ First name: _____

Profession _____ Company / University: _____

Department / Affiliation _____ Address _____

ZIP code _____ Town _____

Country: _____ Phone: _____

Fax: _____ E-Mail: _____

Legally binding Signature: _____ Date: _____

Conference Fees

	Fee 3 days	Fee after April 23	One day	One day after April 23
Academy esnam member	580. -- €	620. -- €	230. -- €	270. -- €
Academy regular	725. -- €	765. -- €	320. -- €	360. -- €
Industry esnam	895. -- €	935. -- €	520. -- €	560. -- €
Industry regular	995. -- €	1'035.-- €	595. -- €	635. -- €
Student esnam member	385. -- €	425. -- €	150. -- €	190. -- €
Student regular	485. -- €	500. -- €	210. -- €	250. -- €

When receiving your registration the organiser shall send to you an invoice to be paid before start of the conference

Evening Event on May 10: Tickets are sold on basis "first come first served"
 Your contribution to the expenses is 50. -- € (please mark)

Please note: A surcharge 25% will be added for registration on site

We accept scanned documents by E-mail and Fax transmissions

Send Registration to the European Foundation for Clinical Nanomedicine, Alemannengasse 12, P.O. Box, CH-4016 Basel, Switzerland, Phone + 41 61 695 93 95 Fax +41 61 695 93 90 E-Mail clinam@clinam.org

Personal Notes:

Sponsors and Supporters of the 3rd European Conference for Clinical Nanomedicine

